We are live on ! Find out more
LEXXW

Lexaria Bioscience Warrant
LEXXW

Delisted

LEXXW was delisted on the 13th of January, 2026.

Back to rankings

3 hedge funds and large institutions have $123K invested in Lexaria Bioscience Warrant in 2023 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% less capital invested

Capital invested by funds: $134K → $123K (-$10.5K)

40% less funds holding

Funds holding: 5 → 3 (-2)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
3
Holders Change
-2
Holders Change %
-40%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$42K
2
Citadel Advisors
Citadel Advisors
Florida
-$2.2K
3
CH
CVI Holdings
Delaware
-$116
4
UBS Group
UBS Group
Switzerland
-$24
Name Holding Trade Value Shares
Change 		Change in
Stake
BFM
1
Boothbay Fund Management
New York
$98.7K – – –
CH
2
CVI Holdings
Delaware
$18.7K -$116 -349 -0.8%
Citadel Advisors
3
Citadel Advisors
Florida
$5.96K -$2.2K -6,636 -33%
SM
4
Sabby Management
Florida
– -$42K -209,979 Closed
UBS Group
5
UBS Group
Switzerland
– -$24 -122 Closed

LEXXW Hedge Fund Activity: Q4 2023 in Review

3 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience Warrant (LEXXW) for Q4 2023, worth a combined $123K — down 7.9% from $134K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of LEXXW and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 0 added.

The largest seller was Sabby Management, exiting entirely with an estimated $42K sold.

  • 3 institutional investors held Lexaria Bioscience Warrant (LEXXW) as of Q4 2023, down from 5 in Q3 2023.
  • Funds reported $123K of Lexaria Bioscience Warrant stock for Q4 2023, down 7.9% quarter-over-quarter.
  • 0 funds opened new Lexaria Bioscience Warrant positions in Q4 2023 and 2 closed out, a net change of -2 holders.
  • The largest Lexaria Bioscience Warrant seller in Q4 2023 was Sabby Management, an estimated $42K sold.

Based on aggregated 13F filings for Q4 2023.